EUVIMEDEUVIMED entdecken
Crossref

Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder

Jacob T Brown iD, Elise N Durgin, Courtney Paetznick, Jeffrey R Bishop, Benjamin Deonovic, Laylia Yang, David A Watson, David B Gregornik

Journal of Child and Adolescent Psychopharmacology · 01.10.2026 · 36 (8) · 493-499

DOI: 10.1177/10445463261467214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 10.07.2026. Verfasst von Jacob T Brown und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota, USA. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Attention Deficit Disorder with Hyperactivity, Cytochrome P-450 CYP2D6, Adrenergic Uptake Inhibitors. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The primary aim of this study was to determine whether CYP2D6 phenotypes are associated with atomoxetine treatment outcomes in children and adolescents with attention-deficit hyperactivity disorder. Patients and Methods: Patients 21 years and younger with a known CYP2D6 genotype and a prescription for atomoxetine were included in this electronic health record review. The primary outcome was defined as discontinuation of atomoxetine due to a lack of efficacy or due to toxicity. CYP2D6 activity scores were adjusted to account for phenoconversion if patients were concomitantly taking a CYP2D6 inhibitor medication.

Results

Of 108 patients that met inclusion criteria, including 13 poor, 30 intermediate, 61 normal, and 4 ultra-rapid CYP2D6 metabolizers after adjusting for phenoconversion. Normal/ultrarapid metabolizers were significantly more likely to discontinue atomoxetine due to lack of efficacy (subdistribution hazard ratio [sHR] = 1.9, p = 0.04), while poor/intermediate metabolizers were significantly more likely to stop due to toxicity (sHR 0.4, p = 0.03). A significant nonlinear effect of adjusted activity score on likelihood of discontinuation due to lack of efficacy ( p < 0.001) or toxicity ( p < 0.001) was identified, where higher CYP2D6 activity scores were associated with more discontinuation due to lack of efficacy and lower activity scores were associated with more discontinuation due to toxicity. When CYP2D6 genotype was available prior to prescribing atomoxetine in intermediate/poor metabolizers, lower median initial doses were observed (0.5 mg/kg/day) compared to those who underwent CYP2D6 genotyping after the initial atomoxetine prescription (0.8 mg/kg/day).

Conclusion

Patients with normal or increased CYP2D6 phenotypes may be more likely to discontinue atomoxetine due to a lack of efficacy, while those with reduced function CYP2D6 phenotypes may be more likely to discontinue atomoxetine due to toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCytochrome P-450 CYP2D6Adrenergic Uptake InhibitorsHumansAdolescentChildFemalePhenotypeMaleGenotypeTreatment OutcomeYoung AdultCytochrome P-450 CYP2D6 Inhibitors

Stichwörter der Autor:innen

ADHDCYP2D6atomoxetinepediatricspharmacogenetics

Substanzen

Atomoxetine HydrochlorideCytochrome P-450 CYP2D6Adrenergic Uptake InhibitorsCytochrome P-450 CYP2D6 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota, USA.
  • Cuyuna Regional Medical Center, Crosby, Minnesota, USA.
  • Children's Minnesota, Minneapolis and Saint Paul, Minneapolis, Minnesota, USA.
  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Children's Minnesota, Minneapolis, Minnesota, USA.
  • William S Middleton Memorial Veterans' Hospital, Madison, Wisconsin, USA.

ORCID-Profile: Jacob T Brown

Zitieren

APA

Brown, J. T., Durgin, E. N., Paetznick, C., Bishop, J. R., Deonovic, B., Yang, L., Watson, D. A., & Gregornik, D. B. (2026). Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 36(8), 493-499. https://doi.org/10.1177/10445463261467214

Vancouver

Brown JT, Durgin EN, Paetznick C, Bishop JR, Deonovic B, Yang L, et al. Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 2026;36(8):493-499. doi:10.1177/10445463261467214

BibTeX
@article{Brown2026,
  author = {Brown, Jacob T and Durgin, Elise N and Paetznick, Courtney and Bishop, Jeffrey R and Deonovic, Benjamin and Yang, Laylia and Watson, David A and Gregornik, David B},
  title = {Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {8},
  pages = {493--499},
  doi = {10.1177/10445463261467214}
}
Kostenlos starten →